Splenic Marginal Zone Lymphoma: Rituximab with Zanubrutinib

We are comparing the effects of adding zanubrutinib to rituximab versus using rituximab alone in patients with untreated splenic marginal zone lymphoma. The goal is to see if the combination improves survival and response rates.

>2 years 11-15 visits Confirmation phase (III)No Placebo Standard Medicines Oral InjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Truxima

Truxima is a medicine used to treat certain blood cancers and some autoimmune diseases by targeting and reducing harmful immune cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Rituximab

Rituximab is a substance that targets and reduces B cells, a type of white blood cell, to treat some blood cancers and autoimmune conditions.

Zanubrutinib

Zanubrutinib is a substance that treats certain B‑cell blood cancers by blocking a protein that helps cancerous B cells grow.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Blitzima

Ituxredi

Mabthera

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Medical University Of Vienna

Department of Medicine I, Division of Oncology

Vienna, Austria

Centre Hospitalier Universitaire Grenoble Alpes

Hematology

Allières-et-Risset, France

Institut Bergonie

Hematology

Bordeaux, France

Sponsor: Association International Extranodal Lymphoma Study Group

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.